Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Thieme, M; Lichtenberg, M; Brodmann, M; Cioppa, A; Scheinert, D.
Lutonix® 014 DCB global Below the Knee Registry Study: interim 6-month outcomes.
J CARDIOVASC SURG. 2018; 59(2): 232-236. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Brodmann Marianne
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
The most common clinical presentation of peripheral artery disease (PAD) comprises intermittent claudication (IC), but about one third of patients will progress to critical limb ischemia (CLI), characterized by rest pain and/or tissue loss, which is the most severe limb manifestation of PAD. Paclitaxel-coated balloons are well established for the endovascular treatment of femoropopliteal lesions in patients with IC and CLI. This ongoing multicenter registry study is exploring the role of the Lutonix® 014 drug-coated balloon (DCB) in the treatment of below-the-knee (BTK) arteries and CLI. Three hundred fourteen (314) patients were enrolled from 26 sites and 12 countries. The real-world patients represent those undergoing intervention for BTK arteries with the Lutonix® 014 DCB. The study had both, primary safety and primary efficacy endpoints. The primary safety endpoint was freedom at 30 days from BTK major adverse limb event (MALE) + perioperative death (POD). Primary efficacy was freedom from clinically driven target lesion reintervention (fTLR) at 6 months. Additional secondary endpoints related to safety were reported. The interim 6 months' results showed freedom from MALE and POD at 30 days of 98.6% and at 6 months (180 days) of 96.0%. Primary efficacy of fTLR at 6 months (180 days) was 87.9%. Safety related secondary endpoints at 6 months (180 days) showed freedom from all of the following: all cause death of 91.2%, above ankle amputation 97.1%, reintervention for thrombosis 95.2%, reintervention for distal embolization 100.0%, and target vessel revascularization of 88.0%. There were no unexpected device or drug related events reported. The interim 6-month outcomes demonstrate the safety and efficacy of the Lutonix® 014 DCB for the treatment of BTK arteries.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Aged, 80 and over -
Amputation -
Angioplasty, Balloon - adverse effects
Angioplasty, Balloon - instrumentation
Angioplasty, Balloon - mortality
Coated Materials, Biocompatible -
Equipment Design -
Europe -
Female -
Humans -
Intermittent Claudication - diagnosis
Intermittent Claudication - mortality
Intermittent Claudication - physiopathology
Intermittent Claudication - therapy
Ischemia - diagnosis
Ischemia - mortality
Ischemia - physiopathology
Ischemia - therapy
Limb Salvage -
Lower Extremity - blood supply
Male -
Middle Aged -
Peripheral Arterial Disease - diagnosis
Peripheral Arterial Disease - mortality
Peripheral Arterial Disease - physiopathology
Peripheral Arterial Disease - therapy
Prospective Studies -
Registries -
Risk Factors -
Time Factors -
Treatment Outcome -
Vascular Access Devices -
Vascular Patency -

Find related publications in this database (Keywords)
Angioplasty, balloon
Atherosclerosis
Device approval
Paclitaxel
© Meduni Graz Impressum